Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Genzyme, Sanofi Advance Negotiations | Contract Pharma

What are you searching for?

Sign in
Breaking News

Genzyme, Sanofi Advance Negotiations

Due diligence phase begins in slow-motion acquisition

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Genzyme and Sanofi-Aventis have moved onto a new stage in their merger negotiations. Genzyme’s board has authorized the company to enter into a confidentiality agreement with Sanofi in order to allow Sanofi to conduct due diligence. Discussions between the companies’ advisors and representatives are ongoing and are focused on the potential use of a contingent value right for alemtuzumab as a part of a potential resolution of the differences in valuation between the parties. The two sides have also discussed other potential terms for a negotiated transaction.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters